Clinical Trials
24 trialsThe Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Chongqing University Cancer Hospital
SPARC-1
Columbia University
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
Zhejiang University
NLCCRIT-LARC
Peking University People's Hospital
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Emory University
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
PanCAN-SR1
Pancreatic Cancer Action Network
TORCH
Fudan University
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
Chang Gung Memorial Hospital
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling
Tongji Hospital
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Capital Medical University
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HEAIS001
Zhejiang Hospital
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)
Centre hospitalier de l'Université de Montréal (CHUM)
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Asan Medical Center
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
University of Pittsburgh
Lymvac-2
Oslo University Hospital
Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
University of Michigan Rogel Cancer Center